Key result
Adding alpha-1-antitrypsin to Custodiol improves LV systolic function ~55% after prolonged cold ischemia.
Why the study?
Donor heart shortages and ischemia/reperfusion injury restrict heart transplantation, and whether human alpha-1-antitrypsin added to preservation solution reduces graft dysfunction after prolonged cold ischemia was investigated.
Does adding human alpha-1-antitrypsin to preservation solution Custodiol improve left-ventricular graft function after prolonged cold ischemic storage in a rat model of heart transplantation?
Does adding human alpha-1-antitrypsin to preservation solution Custodiol improve left-ventricular graft function after prolonged cold ischemic storage in a rat model of heart transplantation?
Absolute Event Rate: 2858% vs 1843%
p-value: p=<0.05
Adding human alpha-1-antitrypsin to Custodiol preservation solution improves left-ventricular graft function and reduces neutrophil infiltration after prolonged cold ischemia in a rat heart transplantation model.
Hypothesis-generating for AAT in cardiac preservation; requires human trials before any clinical consideration.
Introduction The shortage of available donor hearts and the risk of ischemia/reperfusion injury restrict heart transplantation (HTX). Alpha-1-antitrypsin (AAT), a well-characterized inhibitor of neutrophil serine protease, is used in augmentation therapy to treat emphysema due to severe AAT deficiency. Evidence demonstrates its additional anti-inflammatory and tissue-protective effects. We hypothesized that adding human AAT in a preservation solution reduces graft dysfunction in a rat model of HTX following extended cold ischemic storage. Methods The hearts from isogenic Lewis donor rats were explanted, stored for either 1h or 5h in cold Custodiol supplemented with either vehicle (1h ischemia, n=7 or 5h ischemia, n=7 groups) or 1 mg/ml AAT (1h ischemia+AAT, n=7 or 5h ischemia+AAT, n=9 groups) before heterotopic HTX. Left-ventricular (LV) graft function was evaluated in vivo 1.5h after HTX. Immunohistochemical detection of myeloperoxydase (MPO) was performed in myocardial tissue and expression of 88 gene quantified with PCR was analyzed both statistical and with machine-learning methods. Results After HTX, LV systolic function (dP/dt max 1h ischemia+AAT 4197 ± 256 vs 1h ischemia 3123 ± 110; 5h ischemia+AAT 2858 ± 154 vs 5h ischemia 1843 ± 104mmHg/s, p <0.05) and diastolic function (dP/dt min 5h ischemia+AAT 1516 ± 68 vs 5h ischemia 1095 ± 67mmHg/s, p <0.05) at an intraventricular volume of 90µl were improved in the AAT groups compared with the corresponding vehicle groups. In addition, the rate pressure product (1h ischemia+AAT 53 ± 4 vs 1h ischemia 26 ± 1; 5h ischemia+AAT 37 ± 3 vs 5h ischemia 21 ± 1mmHg*beats/min at an intraventricular volume of 90µl; p <0.05) was increased in the AAT groups compared with the corresponding vehicle groups. Moreover, the 5h ischemia+AAT hearts exhibited a significant reduction in MPO-positive cell infiltration in comparison to the 5h ischemia group. Our computational analysis shows that ischemia+AAT network displays higher homogeneity, more positive and fewer negative gene correlations than the ischemia+placebo network. Discussion We provided experimental evidence that AAT protects cardiac grafts from prolonged cold ischemia during HTX in rats.
No takes yet. Share an insight, caveat, or question.
Korkmaz‐Icöz et al. (2023) studied Ischemia/reperfusion injury in heart transplantation (n=30). Alpha-1-antitrypsin (AAT) vs. Custodiol supplemented with human albumin vehicle was evaluated on Left-ventricular systolic function (dP/dtmax) at an intraventricular volume of 90µl after 5h ischemia (p=<0.05). Adding human alpha-1-antitrypsin to Custodiol preservation solution significantly improved left-ventricular systolic function after prolonged (5h) cold ischemia compared to vehicle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: